Tumor Biology

, Volume 35, Issue 1, pp 561–565 | Cite as

Association between p53 Arg72Pro polymorphism and thyroid cancer risk: a meta-analysis

Research Article

Abstract

The p53 is a tumor suppressor gene which may be involved in the development of thyroid cancer. Studies investigating the association between p53 Arg72Pro polymorphism and thyroid cancer risk reported conflicting results. The aim of the meta-analysis was to derive a more precise assessment of the association between p53 Arg72Pro polymorphism and thyroid cancer risk. A literature search of PubMed and Web of Science from their inception through March 2013 was conducted. Odds ratios (OR) with 95 % confidence intervals (95 % CI) were used to assess the strength of the association. Eight case–control studies were included with a total of 874 thyroid cancer cases and 1,891 controls. The meta-analysis results showed that the p53 Arg72Pro polymorphism was only associated with thyroid cancer risk under the recessive model (ProPro vs. ArgArg/ArgPro: OR = 1.83, 95 % CI 1.05–3.20, P = 0.034). However, there was no significant association between p53 Arg72Pro polymorphism and thyroid cancer risk under the other three genetic models (Pro vs. Arg: OR = 1.20, 95 % CI 0.87–1.67, P = 0.262; ProPro vs. ArgArg: OR = 1.75, 95 % CI 0.88–3.50, P = 0.113; ProPro/ArgPro vs. ArgArg: OR = 1.01, 95 % CI 0.66–1.55, P = 0.968). Subgroup by ethnicity showed that there was no significant association between p53 Arg72Pro polymorphism and thyroid cancer risk in both Caucasians and Asians. Thus, p53 Arg72Pro polymorphism may be associated with thyroid cancer risk, and ProPro genotype is likely to be a risk factor of thyroid cancer.

Keywords

Thyroid cancer p53 Polymorphism Meta-analysis 

Notes

Conflicts of interest

None

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Goyal N, Setabutr D, Abdulghani J, Goldenberg D. Molecular and genetic markers of follicular-cell thyroid cancer: etiology and diagnostic and therapeutic opportunities. Adv Exp Med Biol. 2013;779:309–26.PubMedCrossRefGoogle Scholar
  3. 3.
    McLeod DS, Sawka AM, Cooper DS. Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet. 2013;381:1046–57.PubMedCrossRefGoogle Scholar
  4. 4.
    Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13:184–99.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381:1058–69.PubMedCrossRefGoogle Scholar
  6. 6.
    Alt FW, Zhang Y, Meng FL, Guo C, Schwer B. Mechanisms of programmed DNA lesions and genomic instability in the immune system. Cell. 2013;152:417–29.PubMedCrossRefGoogle Scholar
  7. 7.
    Papamichos-Chronakis M, Peterson CL. Chromatin and the genome integrity network. Nat Rev Genet. 2013;14:62–75.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Hunt CR, Ramnarain D, Horikoshi N, Iyengar P, Pandita RK, Shay JW, et al. Histone modifications and DNA double-strand break repair after exposure to ionizing radiations. Radiat Res. 2013;179:383–92.PubMedCrossRefGoogle Scholar
  9. 9.
    Wade M, Li YC, Wahl GM. Mdm2, mdmx and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13:83–96.PubMedCrossRefGoogle Scholar
  10. 10.
    Bellini MF, Cadamuro AC, Succi M, Proenca MA, Silva AE. Alterations of the tp53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol. 2012;2012:891961.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Habbous S, Pang V, Eng L, Xu W, Kurtz G, Liu FF, et al. P53 arg72pro polymorphism, hpv status and initiation, progression, and development of cervical cancer: a systematic review and meta-analysis. Clin Cancer Res. 2012;18:6407–15.PubMedCrossRefGoogle Scholar
  12. 12.
    Boltze C, Roessner A, Landt O, Szibor R, Peters B, Schneider-Stock R. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. Int J Oncol. 2002;21:1151–4.PubMedGoogle Scholar
  13. 13.
    Granja F, Morari J, Morari EC, Correa LA, Assumpcao LV, Ward LS. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett. 2004;210:151–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Bufalo NE, Leite JL, Guilhen AC, Morari EC, Granja F, Assumpcao LV, et al. Smoking and susceptibility to thyroid cancer: an inverse association with cyp1a1 allelic variants. Endocrinol Relat Cancer. 2006;13:1185–93.CrossRefGoogle Scholar
  15. 15.
    Rogounovitch TI, Saenko VA, Ashizawa K, Sedliarou IA, Namba H, Abrosimov AY, et al. Tp53 codon 72 polymorphism in radiation-associated human papillary thyroid cancer. Oncol Rep. 2006;15:949–56.PubMedGoogle Scholar
  16. 16.
    Siraj AK, Al-Rasheed M, Ibrahim M, Siddiqui K, Al-Dayel F, Al-Sanea O, et al. Rad52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in middle eastern population. J Endocrinol Investig. 2008;31:893–9.Google Scholar
  17. 17.
    Akulevich NM, Saenko VA, Rogounovitch TI, Drozd VM, Lushnikov EF, Ivanov VK, et al. Polymorphisms of DNA damage response genes in radiation-related and sporadic papillary thyroid carcinoma. Endocrinol Relat Cancer. 2009;16:491–503.CrossRefGoogle Scholar
  18. 18.
    Reis AA, Silva DM, Curado MP, da Cruz AD. Involvement of cyp1a1, gst, 72tp53 polymorphisms in the pathogenesis of thyroid nodules. Genet Mol Res. 2010;9:2222–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Barbieri RB, Bufalo NE, Cunha LL, Assumpção LV, Maciel RM, Cerutti JM, et al. Genes of detoxification are important modulators of hereditary medullary thyroid carcinoma risk. Clin Endocrinol (Oxf). 2013;79(2):288–93. doi: 10.1111/cen.12136.CrossRefGoogle Scholar
  20. 20.
    Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRefGoogle Scholar
  21. 21.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  22. 22.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  23. 23.
    Weng Y, Lu L, Yuan G, Guo J, Zhang Z, Xie X, et al. P53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis. PLoS One. 2012;7:e45820.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.Department of EndocrinologyShengjing Hospital of China Medical UniversityShenyangChina
  2. 2.Department of EndocrinologyFourth Affiliated Hospital of China Medical UniversityShenyangChina

Personalised recommendations